Dr Rosol prepared remarks
"On
the therapeutic assets front, we are advancing our candidates in the
oncology and anti-inflammatory spaces in preclinical studies with the
goal of filing investigational new drug applications to advance to human
trials in 2024. These filings will be significant inflection points and
opportunities for licensing and partnering deals for the company."
but obviously need the money
Question
You
did an excellent answer. So my follow-up on that is an observation that
I can make, and maybe you can't opine on it. But I think it's opening
up the IND that will really open this up to the world. And on that, do
you have any other guideline you can give us into 2024 on your target
range for that IND?
Dr. Rosol
Yes,
sorry. Thanks. I think that's still our goal and our objective.
Obviously, it will be really helped -- will have significant help
propelling us forward with full funding, but that is still an achievable
goal because we've advanced some of these significantly in the
preclinical space. And what you want to do to get towards that IND, the
other kind of 2 dominoes that need to fall, roughly speaking or at a
high level, are you need to establish that in preclinical models that
your construct or your therapy is safe and tolerated, and there are some
specific studies you have to do for that. But they're very well known
and established and we can box those out, and we've already accounted
for those in our time line.
And
then the other thing you have to do is show that you can actually make
the drug in a scalable fashion and it's reliable and safe to be
injected. And so those are the other 2 dominoes that need to fall. It's
fairly reasonable for us, we think, to get to those in the time lines
you've seen with the caveat always we need to be resourced properly.
